U.S. pharma giant copyright scrapped two experimental weight loss tablets final calendar year—a once-every day tablet, lotiglipron, as a consequence of elevated liver enzymes plus a twice-daily capsule, danuglipron, on account of solid Uncomfortable side effects—but CEO Albert Bourla has stated the company is determined to “Participate in and